Neoantigen Detection Using Guard Molecules for Mass Spectrometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and quantifying neoantigens from clinical samples are not sensitive, rapid, or reproducible enough for routine clinical applications, especially with limited tumor tissue available from biopsies or surgical resections, hindering the establishment of personalized cancer treatments.
Innovation Solution
The Valid-NEO pipeline integrates a method and system for neoantigen detection and quantification using guard molecules with similar characteristics to target peptides, which are distinguishable by mass spectrometry, and an automated system for sample preparation and analysis, reducing manual intervention and enhancing sensitivity and reproducibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If manual sample processing is used for neoantigen detection, then flexibility in handling diverse samples is maintained, but sensitivity and reproducibility are insufficient for routine clinical applications
Solution Approach 1:
The patent introduces guard molecules as intermediary substances that compete with neoantigens for binding to HLA molecules during sample preparation. These guard molecules are designed with similar characteristics to target neoantigens but are distinguishable by mass spectrometry, thereby protecting the detection system and improving measurement precision without requiring complex automated equipment
Solution Approach 2:
The patent creates synthetic copies of neoantigens (guard molecules) that mimic the physical and chemical properties of actual target peptides. These copies are used in excess to saturate non-specific binding sites and protect against sample loss, enabling high sensitivity detection while maintaining simple manual processing workflows
2Reliability
If extensive manual sample processing is performed, then sample preparation flexibility is maintained, but sample loss increases and reproducibility decreases
Solution Approach 1:
The patent performs preliminary enrichment of HLA molecules and neoantigens from clinical samples before mass spectrometry analysis. By pre-concentrating the target molecules and removing bulk proteins through immunoprecipitation and chromatography steps, the method reduces sample loss and improves reproducibility of subsequent detection
Solution Approach 2:
Guard molecules serve as protective intermediaries that compete for binding sites during sample preparation. By adding these surrogate molecules in excess, the system prevents non-specific adsorption and degradation of actual neoantigens, thereby reducing sample loss and improving reproducibility across multiple processing steps
3Measurement precision
If current detection methods are used, then existing equipment can be utilized, but detection sensitivity and quantification accuracy are insufficient for limited clinical samples
Solution Approach 1:
The patent extracts and enriches neoantigens from complex clinical samples by immunoprecipitating HLA molecules and eluting bound peptides. This extraction process concentrates the target neoantigens from limited sample amounts, enabling accurate quantification with as little as 10^6 tumor cells while maintaining high measurement precision
Solution Approach 2:
The patent employs mass spectrometry with selected reaction monitoring (SRM) to detect neoantigens, utilizing the mass-to-charge ratio parameter to distinguish target peptides from background. By optimizing fragmentation patterns and transition-specific detection parameters, the method achieves high quantification accuracy from minimal sample amounts
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves high sensitivity and reproducibility in neoantigen detection and quantification, enabling direct validation from clinical samples and paving the way for truly personalized cancer therapeutics with minimal sample loss and improved transplantability across diagnostic centers.
Implementation Method 1
each of the at least one guard molecule is configured to have an M/z value that is distinguishable from the target peptide by the mass spectrometry analysis
Data Source
AI summary
A method for characterizing a target peptide through a detection approach such as mass spectrometry is provided, including: introducing at least one guard molecule to mix with the target peptide; and applying the detection approach for the characterization of the target peptide. Each guard molecule is configured to have similar characteristics as the target peptide, yet is still distinguishable therefrom by the detection approach, such as having a mass spectrometry-distinguishable different M/z value compared with the target peptide. The method can be used to characterize a neoantigen peptide through mass spectrometry, upstream of which the method can further include steps for tissue sample preparation, HLA molecules enrichment, elution, clean-up, and purification. Some or all of these steps can be configured to be executed in a substantially automatic manner with little or no manual intervention. A system for implementing the neoantigen analysis method is further provided.